NCT04386746View on ClinicalTrials.gov

Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

October 4, 2022

Study Completion Date

November 30, 2025

Conditions
Urothelial Carcinoma BladderBladder Cancer
Interventions
DRUG

Gemcitabine

1g gemcitabine in 50ml sterile water; instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.

DRUG

Docetaxel

37.5mg docetaxel in 50ml normal saline solution (NSS); instilled once weekly for 6 weeks and then once monthly for ≤ 21 months.

Trial Locations (1)

21287

Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER